Predicting Degree of Benefit From Adjuvant Trastuzumab in NSABP Trial B-31
Authors:
- Katherine L. Pogue-GeileKPKatherine L. Pogue-Geile
- Chungyeul KimCKChungyeul Kim
- Jong-Hyeon JeongJJJong-Hyeon Jeong
- Noriko TanakaNTNoriko Tanaka
- Hanna BandosHBHanna Bandos
- Patrick G. GavinPGPatrick G. Gavin
- Debora FumagalliDFDebora Fumagalli
- Lynn C. GoldsteinLGLynn C. Goldstein
- Nour SneigeNSNour Sneige
- Eike BurandtEBEike Burandt
- Yusuke TaniyamaYTYusuke Taniyama
- Olga L. BohnOBOlga L. Bohn
Open Access
- 22 November 2013
- journal article
- research article
- Published by Oxford University Press (OUP) in JNCI: Journal of the National Cancer Institute
- Vol. 105 (23) , 1782-1788
Abstract
National Surgical Adjuvant Breast and Bowel Project (NSABP) trial B-31 suggested the efficacy of adjuvant trastuzumab, even in HER2-negative breast cancer. This finding prompted us to develop a predictive model for degree of benefit from trastuzumab using archived tumor blocks from B-31. Case subjects with tumor blocks were randomly divided into discovery (n = 588) and confirmation cohorts (n = 991). A predictive model was built from the discovery cohort through gene expression profiling of 462 genes with nCounter assay. A predefined cut point for the predictive model was tested in the confirmation cohort. Gene-by-treatment interaction was tested with Cox models, and correlations between variables were assessed with Spearman correlation. Principal component analysis was performed on the final set of selected genes. All statistical tests were two-sided. Eight predictive genes associated with HER2 (ERBB2, c17orf37, GRB7) or ER (ESR1, NAT1, GATA3, CA12, IGF1R) were selected for model building. Three-dimensional subset treatment effect pattern plot using two principal components of these genes was used to identify a subset with no benefit from trastuzumab, characterized by intermediate-level ERBB2 and high-level ESR1 mRNA expression. In the confirmation set, the predefined cut points for this model classified patients into three subsets with differential benefit from trastuzumab with hazard ratios of 1.58 (95% confidence interval [CI] = 0.67 to 3.69; P = .29; n = 100), 0.60 (95% CI = 0.41 to 0.89; P = .01; n = 449), and 0.28 (95% CI = 0.20 to 0.41; P < .001; n = 442; Pinteraction between the model and trastuzumab < .001). We developed a gene expression–based predictive model for degree of benefit from trastuzumab and demonstrated that HER2-negative tumors belong to the moderate benefit group, thus providing justification for testing trastuzumab in HER2-negative patients (NSABP B-47).Keywords
This publication has 23 references indexed in Scilit:
- Estrogen Receptor (ESR1) mRNA Expression and Benefit From Tamoxifen in the Treatment and Prevention of Estrogen Receptor–Positive Breast CancerJournal of Clinical Oncology, 2011
- Semiquantitative hormone receptor level influences response to trastuzumab-containing neoadjuvant chemotherapy in HER2-positive breast cancerLaboratory Investigation, 2011
- Side-population cells in luminal-type breast cancer have tumour-initiating cell properties, and are regulated by HER2 expression and signallingBritish Journal of Cancer, 2010
- Supervised Risk Predictor of Breast Cancer Based on Intrinsic SubtypesJournal of Clinical Oncology, 2009
- The Triple Negative Paradox: Primary Tumor Chemosensitivity of Breast Cancer SubtypesClinical Cancer Research, 2007
- Sequential Preoperative or Postoperative Docetaxel Added to Preoperative Doxorubicin Plus Cyclophosphamide for Operable Breast Cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-27Journal of Clinical Oncology, 2006
- Trastuzumab after Adjuvant Chemotherapy in HER2-Positive Breast CancerNew England Journal of Medicine, 2005
- A Multigene Assay to Predict Recurrence of Tamoxifen-Treated, Node-Negative Breast CancerNew England Journal of Medicine, 2004
- Patterns of treatment effects in subsets of patients in clinical trialsBiostatistics, 2004
- Checking the Cox model with cumulative sums of martingale-based residualsBiometrika, 1993